跳到正文
WorldBrand.AI

再生元的争议事件

以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。

返回词条共 6 条

  1. 2021

    Amgen在专利争议中向美国最高法院提交请愿书

    提起诉讼

    Amgen Inc.及其子公司向美国最高法院提交调卷令请愿书，所涉对方为Sanofi Aventisub LLC、Regeneron Pharmaceuticals Inc.和Sanofi-Aventis US, LLC。请愿书涉及专利书面描述要求及其所需的详细程度。

    来源摘录

    • On Monday a petition for certiorari was filed to the Supreme Court of the United States by Amgen Inc. and its subsidiaries against Sanofi Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis US, LLC.
    来源

  2. 2021

    Humana 就涉嫌 Eylea 定价计划起诉 Regeneron

    提起诉讼

    Humana 起诉 Regeneron，指控 Regeneron 与 Chronic Disease Foundation 涉及一项 Eylea 相关计划，欺诈 Medicare 及其签约支付方。诉状称 Regeneron 抬高 Eylea 价格并向该基金会提供非法回扣；这些是指控，并非已陈述的法院认定。

    来源摘录

    • Humana Inc. filed suit against Regeneron Pharmaceuticals, Inc. Thursday in the Southern District of New York over allegations that the pharmaceutical company engaged in a scheme with the Chronic Disease Foundation. The plaintiff claims that as a result of this purported scheme, which they believe is a “sham charity,” the two parties defrauded Medicare and its contracted payors out of hundreds of millions of dollars.
    • The plaintiff said that Regeneron inflated the price of Eylea and then provided illegal kickbacks to the CDF, which then used the tainted donations they received from Regeneron to cover cost-sharing obligations for patients so that they would continue to choose Eylea rather than its less expensive alternatives.
    来源

  3. 2021

    股东顾问机构批评再生元高管薪酬安排

    公众反弹

    股东顾问机构Glass Lewis和Institutional Shareholder Services批评再生元向高管发放的预付股票奖励金额过高，并质疑其是否符合股东利益。报道还指出，近年来股东对公司高管薪酬安排存在显著反对。

    来源摘录

    • The investor advisory group Glass Lewis said it was “highly concerned” at the New York-based firm’s decision last year to ditch annual stock options.
    • Institutional Shareholder Services, another advisory group, also expressed concern: “The awards are excessive in value, replace annual grants for a relatively long period of time, and provide multiple opportunities for the same shares to be earned.”
    • The US drugmaker Regeneron, whose Covid treatment was hailed as a “cure” by Donald Trump last year, has come under fire from two influential shareholder advisory groups over “excessive” payouts made to its top executives ahead of its annual meeting on Friday.
    来源

  4. 2020

    美国司法部就患者慈善援助款项起诉再生元

    提起诉讼

    美国司法部对再生元提起民事诉讼，指控该公司非法向患者组织付款，以支付使用其 Eylea 治疗的 Medicare 患者费用。再生元称相关指控毫无根据，并表示将为案件辩护。

    品牌回应

    • 否认 — Regeneron

      Regeneron said there was no merit to DOJ's allegations.

    来源摘录

    • The civil complaint, filed in the US District Court in Massachusetts, alleges that Regeneron violated the anti-kickback statute, which prohibits drug companies from paying — directly or indirectly — for Medicare patients to use their drugs.
    来源

  5. 2020

    赛诺菲停止 Kevzara 新冠临床试验

    整改

    在试验发现部分患者出现包括肺炎和死亡在内的不良反应后，赛诺菲停止了 Kevzara 用于新冠治疗的临床试验。该公司表示不再计划开展该药物的进一步新冠临床研究。该事件在报道中与 Kevzara 相关品牌再生元一同出现。

    来源摘录

    • Sanofi has stopped the clinical trials of Kevzara, one of the drugs being tested to treat COVID-19.
    • On Tuesday, Sanofi said it had no longer plans to conduct further clinical studies for Kevzara in COVID-19
    • It manufactures Kevzara in partnership with American firm Regeneron.
    来源

  6. 2020

    美国就涉嫌 Eylea 回扣起诉 Regeneron

    提起诉讼

    美国司法部起诉 Regeneron，指控该公司通过共付援助基金就 Eylea 支付回扣。案件涉及虚假索赔指控，并寻求三倍损害赔偿；本文未将这些指控作为已认定事实。

    来源摘录

    • The company is accused of “funneling tens of millions of dollars through a co-pay foundation, the Chronic Disease Fund (CDF),” and liberating Medicare patients from paying co-pays for the drug.
    • The Justice Department sued Regeneron Pharmaceuticals, Inc. on Wednesday for making kickback payments for macular degeneration drug Eylea.
    • The Justice Department seeks an award of treble damages as a result of Regeneron’s allegedly false claims.
    来源